Dashboard
Manage Tickers

CHRS Coherus BioSciences, Inc.

Nasdaq coherus.com


$ 1.36 $ 0.00 (0 %)    

Wednesday, 12-Nov-2025 07:14:07 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 625.10 $ 0.00 (0 %)
DIA $ 480.56 $ 0.00 (0 %)
SPY $ 685.29 $ 0.00 (0 %)
TLT $ 89.79 $ 0.00 (0 %)
GLD $ 380.46 $ 0.00 (0 %)
$ 1.35
$ 1.26
$ 1.35 x 86,219
$ 1.38 x 112
-- - --
$ 0.70 - $ 2.43
2,101,872
na
163.18M
$ 1.33
$ 1.05
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-12-2025 03-31-2025 10-Q
4 03-17-2025 12-31-2024 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-15-2024 12-31-2023 10-K
9 11-06-2023 09-30-2023 10-Q
10 08-02-2023 06-30-2023 10-Q
11 05-08-2023 03-31-2023 10-Q
12 03-06-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-23-2022 12-31-2021 10-K
17 11-08-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 02-27-2020 12-31-2019 10-K
25 11-08-2019 09-30-2019 10-Q
26 08-05-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 02-28-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-08-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-08-2018 12-31-2017 10-K
33 11-06-2017 09-30-2017 10-Q
34 08-07-2017 06-30-2017 10-Q
35 05-08-2017 03-31-2017 10-Q
36 03-14-2017 12-31-2016 10-K
37 11-09-2016 09-30-2016 10-Q
38 08-09-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 02-29-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

coherus-oncology-presents-new-multiomic-tumor-and-blood-based-biomarker-data-from-phase-1b-clinical-study-evaluation-chs-114-antibody-in-patients-with-recurrentmetastatic-head-and-neck-squamous-cell-carcinoma
Coherus Oncology Presents New Multiomic Tu...
11/07/2025 14:16:47

Coherus Oncology, Inc. (NASDAQ: CHRS), today announced new multiomic tumor and blood-based biomarker data from the dose expansi...

coherus-biosciences-q3-adj-eps-033-misses-029-estimate-sales-11571m-miss-13413m-estimate
Coherus BioSciences Q3 Adj. EPS $(0.33) Mi...
11/06/2025 21:22:16

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of...

earnings-scheduled-for-november-6-2025
Earnings Scheduled For November 6, 2025
11/06/2025 11:12:19

coherus-biosciencess-earnings-outlook
Coherus BioSciences's Earnings Outlook
11/05/2025 20:03:43

4-biotechnology-stocks-lead-momentum-gains-amid-strong-technicals
4 Biotechnology Stocks Lead Momentum Gains...
10/10/2025 08:32:04

4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.

coherus-oncology-to-present-chs-114-anti-ccr8-data-at-sitc-2025-and-highlight-mechanism-in-cancer-io-webinar-series
Coherus Oncology To Present CHS-114 Anti-C...
10/03/2025 13:10:29

this-brinker-international-analyst-turns-bullish-here-are-top-5-upgrades-for-thursday
This Brinker International Analyst Turns B...
09/04/2025 14:05:42

maxim-group-upgrades-coherus-oncology-to-buy-announces-4-price-target
Maxim Group Upgrades Coherus Oncology to B...
09/04/2025 12:09:18

Maxim Group analyst Jason McCarthy upgrades Coherus Oncology (NASDAQ:CHRS) from Hold to Buy and announces $4 price target.

coherus-biosciences-q2-adj-eps-034-misses-028-estimate-sales-10254m-miss-10946m-estimate
Coherus BioSciences Q2 Adj. EPS $(0.34) Mi...
08/07/2025 21:16:37

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

insights-ahead-coherus-biosciencess-quarterly-earnings
Insights Ahead: Coherus BioSciences's Quar...
08/06/2025 21:06:18

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
07/03/2025 21:05:44

coherus-biosciences-announces-clinical-collaboration-with-storm-therapeutics-to-evaluate-stc-15-mettl3-inhibitor-in-combination-with-loqtorzi-next-gen-pd-1-inhibitor-in-phase-1b2-study-for-nsclc-hnscc-melanoma-and-endometrial-cancer-treatment
Coherus BioSciences Announces Clinical Col...
05/27/2025 12:36:21

Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. ...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
05/13/2025 12:10:18

coherus-biosciences-q1-adj-eps-035-up-from-048-yoy-sales-760m-up-from-231m-yoy
Coherus BioSciences Q1 Adj. EPS $(0.35) Up...
05/12/2025 20:23:29

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.35) per share. This is a 27.08 percent increase over losses ...

Core News & Articles
Earnings Scheduled For May 12, 2025
05/12/2025 08:32:31

earnings-preview-coherus-biosciences
Earnings Preview: Coherus BioSciences
05/09/2025 20:05:58

hc-wainwright--co-reiterates-buy-on-coherus-biosciences-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Cohe...
04/29/2025 10:45:56

HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $7 price ...

coherus-biosciences-presents-data-from-ongoing-phase-1-clinical-trial-evaluating-chs-114-shows-clinical-efficacy-and-proof-of-mechanism-in-hnscc-in-combination-with-toripalimab
Coherus Biosciences Presents Data From Ong...
04/28/2025 14:12:14

– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial...

coherus-completes-strategic-transformation-with-successful-divestiture-of-udenyca-franchise-says-250m-post-close-cash-balance-extends-cash-runway-over-2-years-into-2027-funding-pipeline-development-through-key-data-catalysts-coherus-to-focus-exclusively-on-its-innovative-novel-oncology-programs
Coherus Completes Strategic Transformation...
04/14/2025 12:11:54

 – $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION